DCF和XELOX方案治疗晚期胃癌的对比研究  

Comparative study of DCF and XELOX regimens in the treatment of advanced gastric cancer

作　　者：夏俊贤[1] 陈敬华[1] 朱美琴[1] 田忠凯[1] 白桦[1] 申维玺[1] 

机构地区：[1]暨南大学第二临床医学院深圳市人民医院肿瘤内科,518020

出　　处：《肿瘤研究与临床》2013年第7期478-480,共3页Cancer Research and Clinic

摘　　要：目的 分析晚期胃癌患者DCF和XELOX化疗方案的疗效和安全性，探讨晚期胃癌治疗适宜的化疗方案。方法 63例晚期胃癌化疗患者，分为A组（DCF方案）31例：多西紫杉醇60～75 mg／m2 第1天；氟尿嘧啶500 mg／m2第1天至第5天，顺铂75 mg／m2，第1天，21 d为1个周期。B组（XELOX方案）32例：奥沙利铂130 mg／m2第1天；卡培他滨1000 mg／m2，2次／d 口服，第1天至第14天。结果 63例均可评价不良反应及客观疗效。A、B两组有效率（完全缓解＋部分缓解）分别为58.1 %和62.5 %；中位生存期分别为10.9个月和11.5个月，两组比较差异均无统计学意义（P＞0.05）；两组不良反应均可耐受，A组骨髓抑制3级以上发生率（16.1 %）比B组（9.3 %）稍高；2～3级以上脱发发生率（77.4 %）比B组（0）高。B组手足综合征毒性发生率（68.8 %）高于A组（9.6 %），肝损伤发生率（37.5 %）比A组（16.1 %）高，但多为轻度。结论 DCF、XELOX方案治疗晚期胃癌疗效相当，不良反应均可耐受。Objective To analyze the efficacy and safety of DCF and XELOX regimens in the treatment of advanced gastric cancer and to explore the appropriate chemotherapy regimen for advanced gastric cancer. Methods 63 patients with advanced gastric cancer were divided into two groups. Group A （31 patients） was administered with DCF regimen, with docetaxel 60-75 mg/m2 on day 1, 5-fluorouracil 500 mg/m2 on day 1 to day 5, cisplatin 75 mg/m2 on day 1, a total cycle of 21 days. Group B （32 patients） was performed with XELOX regimen,with oxaliplatin 130 mg/m2 on day 1, capecitabine 100 mg/m2 twice a day on day 1 to day 14. Results 63 cases were eligible to analyze the efficacy and adverse reactions. The efficient rate （PR＋CR） of group A and B were 58.1 % and 62.5 %, respectively. The median survival time were 10.9 months and 11.5 months, but there were no significant difference between the two groups （P 〉 0.05）. The patients in both groups showed the similar tolerance of adverse reaction. Bone marrow suppression above level 3 in group A （16.1 %） was higher than that in group B （9.3 %）. Hair loss above level 2-3 in group A was higher （77.4 %）. Hand-foot syndrome in group B （68.8 %） was higher than that in group A （9.6 %）. Mild liver function damage in group B （37.5 %） was higher than that in group A （16.1 %）. Conclusion The DCF and XELOX schemes have the similar effect in the treatment of advanced gastric cancer with the tolerate side effect.

关 键 词：胃肿瘤 药物疗法 联合 

分 类 号：R735.2[医药卫生—肿瘤]